AI played key role in designing Moderna's successful skin cancer vaccine

Polymarket · x · 2026-08-20

Moderna and Merck's personalized skin cancer vaccine (mRNA-4157/V940) succeeded in a Phase 3 trial. Reports indicate that AI played a key role in the design process. Polymarket currently gives a 59% chance of FDA approval by the end of 2027.

Related event: Moderna's AI-Designed Personalized mRNA Cancer Vaccine Wins Phase III(23 posts)→

Original post →

More from Apps

Apps channel →